Qsymia Uptake Slow, Steady, but Will It Win Obesity Race?
Four weeks after its launch, 2,000 patients were taking obesity drug Qsymia (phentermine/topiramate), from Vivus Inc., with new patient starts slowing from an initial four- or fivefold increase to a 27 percent to 33 percent increase from week three to week four, according to IMS and Wolters Kluwer weekly prescription data.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter